Bone Biology division, Garvan Institute of Medical Research, Sydney, Australia; Clinical School, St Vincent's Hospital, Faculty of Medicine, University of New South Wales Sydney, Sydney, Australia; Department of Endocrinology and Diabetes, St Vincent's Hospital, Sydney, Australia.
Bone Biology division, Garvan Institute of Medical Research, Sydney, Australia; Clinical School, St Vincent's Hospital, Faculty of Medicine, University of New South Wales Sydney, Sydney, Australia.
Bone. 2022 Jun;159:116373. doi: 10.1016/j.bone.2022.116373. Epub 2022 Feb 26.
Diabetes and fractures are both associated with increased mortality, however the effect of the combination is not well-established. We examined the mortality risk following all types of fractures in type 2 diabetes (T2D).
In the Dubbo Osteoporosis Epidemiology Study (1989-2017), participants were grouped according to T2D and/or incident fracture. Study outcome was all-cause mortality. First incident radiological fragility fracture and incident T2D diagnosis were time-dependent variables. Cox's proportional hazards models quantified mortality risk associated with T2D and incident fracture overall, as well as by fracture site, T2D duration and T2D medication type.
In 3618 participants (62% women), 272 had baseline and 179 developed T2D over median 13.0 years (IQR 8.2-19.6). 796 women (56 with T2D) and 240 men (25 with T2D) sustained a fracture. Compared to those without T2D or fracture, mortality risk increased progressively, in T2D without fracture, then no T2D with fracture, and was highest in those with T2D with fracture (adjusted hazard ratio (aHR) (95% CI) for women 2.62 (1.75-3.93) and men 2.61 (1.42-4.81)). Within T2D participants, incident fracture was associated with increased mortality (aHR for women 1.87 (1.10-3.16) and men 2.83 (1.41-5.68)), especially following hip/vertebral fractures in men (aHR 2.97 (1.29-6.83)) and non-hip non-vertebral fractures in women (aHR 2.42 (1.24-4.75)), and in T2D duration >5 years.
Any fracture in T2D conferred significant excess mortality. Individuals with T2D should be carefully monitored post-fracture, especially if T2D >5 years. Optimising fracture prevention and post-fracture management in T2D is critical and warrants further studies.
糖尿病和骨折都与死亡率增加有关,但两者同时存在的影响尚不清楚。我们研究了 2 型糖尿病(T2D)患者发生各种类型骨折后的死亡风险。
在 Dubbo 骨质疏松症流行病学研究(1989-2017 年)中,参与者根据 T2D 和/或新发骨折进行分组。研究结局为全因死亡率。首次发生的影像学脆性骨折和新发 T2D 诊断为时间依赖性变量。Cox 比例风险模型量化了 T2D 和新发骨折总体以及骨折部位、T2D 持续时间和 T2D 药物类型与死亡率风险的关系。
在 3618 名参与者(62%为女性)中,272 名参与者基线时有 T2D,179 名参与者在中位 13.0 年内(IQR 8.2-19.6)发生 T2D。796 名女性(56 名有 T2D)和 240 名男性(25 名有 T2D)发生骨折。与无 T2D 或骨折的参与者相比,T2D 无骨折者的死亡风险逐渐增加,然后是无 T2D 但有骨折者,而 T2D 合并骨折者的死亡风险最高(女性调整后的危险比(aHR)(95%CI)为 2.62(1.75-3.93),男性为 2.61(1.42-4.81))。在 T2D 参与者中,新发骨折与死亡率增加相关(女性 aHR 为 1.87(1.10-3.16),男性 aHR 为 2.83(1.41-5.68)),尤其是男性髋部/脊柱骨折(aHR 为 2.97(1.29-6.83))和女性非髋部非脊柱骨折(aHR 为 2.42(1.24-4.75)),以及 T2D 持续时间>5 年。
T2D 患者任何骨折都显著增加死亡风险。T2D 患者骨折后应密切监测,尤其是 T2D 持续时间>5 年者。优化 T2D 患者的骨折预防和骨折后管理至关重要,值得进一步研究。